Recently, a range of bispecific constructs targeting 4-1BB-mediated T cell costimulation to PD-L1-overexpressing tumor cells and simultaneously blocking the PD-1/PD-L1 axis have been generated [16,17,18,19,20,21,22] and are being clinically evaluated. Here, PDCD1 is linked to neoplasm.